Prion protein ligands and methods of use

Details Prion protein ligands and methods of use Prion protein ligands and methods of use

2011-01-04

2011-01-04

Lucas, Zachariah (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Reexamination Certificate

active

07863411

ABSTRACT:
Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject.

REFERENCES:
patent: 4849408 (1989-07-01), Sommermeyer et al.
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5036052 (1991-07-01), Ozeki et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5281539 (1994-01-01), Schramm
patent: 5312730 (1994-05-01), Piran et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5525492 (1996-06-01), Hill
patent: 5750361 (1998-05-01), Prusiner et al.
patent: 5808011 (1998-09-01), Gawryl et al.
patent: 5834318 (1998-11-01), Buettner et al.
patent: 5888834 (1999-03-01), Ishikawa et al.
patent: 5958684 (1999-09-01), Van Leeuwen et al.
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6221614 (2001-04-01), Prusiner et al.
patent: 6261790 (2001-07-01), O'Rourke
patent: 6355610 (2002-03-01), Chesebro et al.
patent: 6379905 (2002-04-01), Fishleigh et al.
patent: 6437102 (2002-08-01), Lee et al.
patent: 6451541 (2002-09-01), Winnacker et al.
patent: 6582965 (2003-06-01), Townsend et al.
patent: 6750025 (2004-06-01), Hammond et al.
patent: 6995141 (2006-02-01), Sleath et al.
patent: 7393658 (2008-07-01), Carbonell et al.
patent: 7510848 (2009-03-01), Hammond et al.
patent: 2003/0092094 (2003-05-01), Vey et al.
patent: 2004/0186273 (2004-09-01), Hammond et al.
patent: 91/13904 (1991-09-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO01/71042 (2001-09-01), None
patent: WO 01/77687 (2001-10-01), None
patent: 01/81367 (2001-11-01), None
patent: WO 03/016904 (2003-02-01), None
patent: 2006/102099 (2006-09-01), None
Hardt et al. J. Comp. Path. 2000, vol. 122, p. 43-53.
Li et al. Biochemistry, 2000, vol. 39, p. 6296-6309.
“International Search Report.” Conducted for International Application No. PCT/US03/38343. Patent Cooperation Treaty: Nov. 17, 2004.
Schatzl, et al. “Prion Protein Gene Variation Among Primates.” J. Mol. Biol. 1995, vol. 245, pp. 362-374.
Aubry et al., “N-Methyl Peptides. IV. Water and Beta-Turn in Peptides. Crystal Structure of N-Pivaloyl-L-Prolyl-N, N′-Dimethyl-D-Alaninamide in the Anhydrous and Monohydrated States”,Int. J. Pept. Protein Res., 18: 195-202 (1981).
Caughey, B., et al., “Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glycosaminoglycan and Congo Red”,Journal of Virology, 68: 2135-2141 (1994).
Degrado, W.F., “Design of Peptides and Proteins”,Adv. Protein Chem:.39, 51-124, (1988).
Devlin, J.J. et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”,Science: 249, 404-406 (1990).
Fischer, M.B. et al., “Binding of Disease-Associated Prion Protein to Plasminogen” ,Nature: 408, 479-483 (2000).
Furka, A. et al. “General Method for Rapid Synthesis of Multicomponent Peptide Mixtures”,Int. J. Peptide Protein Res.:37, 487-493 (1991).
Ingrosso, L., et al., “Congo Red Prolongs the Incubation Period in Scrapie-Infected Hamsters”,Journal of Virology: 69, 506-508 (1995).
Jameson, B.A. et al., “A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis”,Nature: 368, 744-746 (1994).
Kascsak, R.J., et al., “Immunodiagnosis of Prion Disease”,Immunological Invest.: 26, 259-268 (1997).
Lam, K.S. et al., “A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity”,Nature: 354,82-84 (1991).
Soto et al., “Reversion Of Prion Protein Conformational Changes By Synthetic β-Sheet Breaker Peptides”,LANCET: 355, 192-197 (2000).
Merrifield, B. “Solid Phase Synthesis”,Science: 232, 341-3479 (1986).
Needleman, S.B. et al. “A General method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”,J. Mol. Biol.: 48, 443-453 (1970).
Pearson, W.R. et al. “Impoved Tools for Biological Sequence Comparison”,Proc. Natl. Acad. Sci. U.S.A.:85, 2444-2448 (1988).
Priola, S.A., et al., “Porphyrin and Phthalocyanine Antiscrapie Compounds”,Science: 287, 1503-1506 (2000).
Prusiner, S.B.,“Molecular Biology of Prion Diseases”,Science: 252, 1515-1522 (1991).
Rose et al. “Turns in Peptides And Proteins”,Molecular Biology of Prion Diseases Adv. Protein Chem.: 37, 1-109 (1985).
Safar, J. et al., “Eight Prion Strains Have PrP(Sc) Molecules With Different Conformations”,Nature Medicine: 4, 1157-1165 (1998).
Samson, W.K. et al. “A 35 Amino Acid Fragment of Leptin Inhibits Feeding in the Rat”,Endocrinology: 137, 5182-5185 (1996).
Soto, C. et al., “Reversion of Prion Protein Conformational Changes in Synthetic Beta-Sheet Breaker Peptides”,Lancet: 355, 192-197 ( 2000).
Stockell, et al., “Prion Protein Selectively Bindes Copper(II) Ions”,Biochemistry: 37, 7185-7193 (1998).
Tagliavani, F., et al., “Effectiveness of Anthracycline Against Experimental Prion Diseases in Syrian Hamsters,”Science: 276, 1119-1122 (1997).
Caspi et al., “The Anti-Prion Activity Of Congo Red”,J. Biol. Chem.: 273, 3484-3489 (1999).
McHattle et al.,“Clusterin Prevents Aggregation Of Neuropeptide 106-126 In Vitro”,Biochem. Biophys. Res. Commun: 259, 336-340 (1999).
Chiarini et al., “Cellular Prion Protein Transduces Neuroprotective Signals,” EMBO (European Molecular Biology Organization) Journal 21(13:3317-26 (2002).
Schmitt-Ulms et al., “Binding of Neural Cell Adhesion Molecules (N-CAMs) to the Cellular Prion Protein,” J. Mol. Biol. 314:1209-25 (2001).
Windl et al., “A Candidate Marsupial PrP Gene Reveals Two Domains Conserved in mammalian Prp Proteins,” Gene 159(181-6 (1995).
Search Report in corresponding EP application 03088431.
Kobayashi et al., “Relative Rates of Monoiodotyrosine and Diiodotyrosine Liberation During Enzymatic Hydrolysis of Iodinated Di- and Tripeptides,” Endocrinology 92(6):1612-6 (1973).
GENESEQP Accession No. AAU49682 (Printed Aug. 9, 2009).
Uniport Accession No. P21734 (Printed Aug. 9, 2009).
Uniport Accession No. P90904 (Printed Aug. 9, 2009).
Uniport Accession No. Q7YX12 (Printed Aug. 9, 2009).
Uniport Accession No. Q8RHT9 (Printed Aug. 9, 2009).
Chen et al., “Fluorescense of Tryptophan Dipeptides: Correlations with the Rotamer Model,” Biochemistry 30: 5184-5195 (1991).
Shimura et al., “Synthetic Oligopeptides as Isoelectric Point Markers for Capillary Isoelectric Focusing with Ultraviolet Absorption Detection,” Electrophoresis 21: 603-610 (2000).

Affiliated with

Also associated with

Rating

Prion protein ligands and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prion protein ligands and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prion protein ligands and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2711038